Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Shares of Vertex Pharmaceuticals Inc. VRTX slid 0.46% to $408.76 Friday, on what proved to be an all-around rough trading ...

Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...

This was the stock's fourth consecutive day of gains.

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $408.18, denoting a +0.72% change from the preceding trading day.

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s ...

Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 ...

We recently compiled a list of the Jim Cramer Talked About These 17 Stocks After The Fed’s Rate Cut. In this article, we are ...

Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...